Protagonist Therapeutics Inc PTGX:NASDAQ

Last Price$29.09NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/09/23
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$27.85 (12)
Ask (Size)$30.30 (18)
Day Low / HighN/A - N/A
Volume725.2 K

View Biotechnology IndustryPeer Comparison as of 06/09/2023


Protagonist Therapeutics Inc ( NASDAQ )

Price: $29.09
Change: -0.27 (0.92%)
Volume: 725.2 K
4:00PM ET 6/09/2023

FibroGen Inc ( NASDAQ )

Price: $16.98
Change: -0.80 (4.50%)
Volume: 1.8 M
4:00PM ET 6/09/2023

Celldex Therapeutics Inc ( NASDAQ )

Price: $34.80
Change: -0.77 (2.16%)
Volume: 501.5 K
4:00PM ET 6/09/2023

Xencor Inc ( NASDAQ )

Price: $26.87
Change: -0.38 (1.39%)
Volume: 176.3 K
4:00PM ET 6/09/2023

BioCryst Pharmaceuticals Inc ( NASDAQ )

Price: $8.52
Change: -0.29 (3.29%)
Volume: 1.6 M
4:00PM ET 6/09/2023

Read more news Recent News

Protagonist Therapeutics Says Oral Drug Candidate JNJ-2113 Showed Pharmacodynamics Activity in Humans in Recent Studies
8:32AM ET 5/12/2023 MT Newswires

Protagonist Therapeutics (PTGX) said Friday data from phase 1 and preclinical studies showed oral drug candidate JNJ-2113 produced systemic...

Sector Update: Health Care Stocks Steady Premarket Wednesday
9:14AM ET 4/05/2023 MT Newswires

Health care stocks were steady premarket Wednesday. The Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) were unchanged...

Protagonist Therapeutics Prices $100 Million Common Stock Offering
3:33AM ET 4/05/2023 MT Newswires

Protagonist Therapeutics (PTGX) said Tuesday it priced its underwritten public offering of 5 million common shares at $20 per share for gross proceeds of...

Protagonist Therapeutics Launches $100 Million Common Stock Offering
5:35PM ET 4/04/2023 MT Newswires

Protagonist Therapeutics (PTGX) said late Tuesday it launched a $100 million public offering of common shares. The biopharmaceutical company expects to...

Company Profile

Business DescriptionProtagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. View company web site for more details
Address7707 Gateway Boulevard
Newark, California 94560-1160
Number of Employees64
Recent SEC Filing06/02/20234
President, Chief Executive Officer & DirectorDinesh V. Patel
Chief Financial Officer & Executive Vice PresidentAsif Ali
Chief Technical Officer & Executive VPMohammad Masjedizadeh
Chief Medical OfficerArturo Molina

Company Highlights

Price Open$29.50
Previous Close$29.36
52 Week Range$6.91 - 29.56
Market Capitalization$1.7 B
Shares Outstanding57.3 M
SectorHealth Technology
Next Earnings Announcement08/03/2023

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.83
Beta vs. S&P 500N/A
Revenue$30.9 M
Net Profit Margin-16,319.91%
Return on Equity-59.44%

Analyst Ratings as of 12/09/2022

Consensus RecommendationConsensus Icon
Powered by Factset